JP Morgan Chase’s Immuneering IMRX Stock Holding History
Bought
Maintained
Sold
Other funds holding IMRX
S
VCM
OCM
JP Morgan Chase's IMRX Position: Q1 2026 in Review
JP Morgan Chase reduced its Immuneering (IMRX) stake by 5.1% in Q1 2026, selling an estimated $1.77K and leaving 6,419 shares worth $31.3K. The position accounts for ﹤0.01% of the portfolio, ranked #6375.
JP Morgan Chase first reported a position in IMRX in Q3 2021 and has held it in 19 quarters since. The position peaked at $170K in Q2 2023. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.
- JP Morgan Chase held 6,419 shares of Immuneering worth $31.3K as of Q1 2026.
- JP Morgan Chase sold 346 Immuneering shares in Q1 2026, an estimated $1.77K.
- Immuneering made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6375 holding.
- JP Morgan Chase first reported a position in Immuneering in Q3 2021 and has held it in 19 quarters since.
- JP Morgan Chase's Immuneering position peaked at $170K in Q2 2023.
- 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.